<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005085</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067695</org_study_id>
    <secondary_id>AECM-T99-0109</secondary_id>
    <secondary_id>NCI-T99-0109</secondary_id>
    <nct_id>NCT00005085</nct_id>
  </id_info>
  <brief_title>Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer</brief_title>
  <official_title>A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who&#xD;
      have metastatic or locally recurrent colorectal cancer. Drugs used in chemotherapy use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the objective response rate of patients with metastatic or locally recurrent&#xD;
      colorectal cancer treated with rebeccamycin analogue.&#xD;
&#xD;
      II. Determine the toxicity of this regimen in this patient population. III. Determine the&#xD;
      effect of this regimen on progression-free and overall survival in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for&#xD;
      a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>becatecarin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic or locally recurrent&#xD;
             adenocarcinoma of the colon or rectum&#xD;
&#xD;
          -  No curable stage of disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
          -  At 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No tumor lesions in previously irradiated area except clearly measurable lesion&#xD;
             documented histologically to be consistent with recurrent tumor in previously&#xD;
             irradiated bed within pelvis&#xD;
&#xD;
          -  The following are considered nonmeasurable disease:&#xD;
&#xD;
               -  Bone lesions Leptomeningeal disease&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
               -  Pleural/pericardial effusion&#xD;
&#xD;
               -  Inflammatory breast disease&#xD;
&#xD;
               -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
               -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
               -  Cystic lesions&#xD;
&#xD;
               -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: ECOG 0-2 OR Karnofsky 60-100%&#xD;
&#xD;
          -  Life expectancy: More than 12 weeks&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
&#xD;
          -  Eligible for placement of a central venous catheter&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to rebeccamycin analogue&#xD;
&#xD;
          -  No other uncontrolled concurrent illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent prophylactic growth factors (e.g., epoetin alfa) except for clinically&#xD;
             defined indication (e.g., filgrastim (G-CSF) for febrile neutropenia)&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (e.g., fluorouracil, oral fluoropyrimidines,&#xD;
             irinotecan, or oxaliplatin) (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent hormones except for clinically defined indication&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (including to bony sites, whole pelvis,&#xD;
             lung, liver, or spinal cord/brain) and recovered&#xD;
&#xD;
          -  No prior total dose of radiotherapy more than 7,000 cGy&#xD;
&#xD;
          -  No prior radiotherapy to 40% or more of total bone marrow&#xD;
&#xD;
          -  No prior radiotherapy to only site of measurable disease&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Recovered from prior therapy 1 prior adjuvant treatment allowed 1 prior treatment for&#xD;
             advanced disease allowed&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent investigational antineoplastic drugs&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent commercial agents for colorectal cancer&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sridhar Mani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2002</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>March 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2004</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

